Home>Topics>Stocks>Exelixis

Exelixis EXEL

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. Can You Handle Risk? With A Dozen Clinical Trials, Exelixis Has Strong Upside Potential

      Headlines

      Tue, 19 Aug 2014

      years to come. While there are always risks involved in this sector, my review of the data and the potential for Exelixis (NASDAQ: EXEL ) makes me believe that shares have strong potential upside from their current levels, if positive data is reported

    2. A Quick Look At 2 Small-Cap Bio-Pharmaceutical Companies: Discovery Labs And Exelixis

      Headlines

      Fri, 1 Aug 2014

      company that has managed to gain FDA approval for a novel product, but has had trouble with marketing. Exelexis (NASDAQ: EXEL ) has been able to create some really great drugs, and has also formed some important partnerships with "big-pharma." Discovery

    3. Exelixis' 2Q Results In Line; Phase III Prostate Cancer Results Later This Year Remain Key Driver

      Commentary

      Fri, 1 Aug 2014

      Exelixis reported second-quarter results that were generally consistent with our ..... year and represent the major catalysts for the firm. During the quarter, Exelixis and partner Roche announced positive top-line results for their Phase

    4. New Morningstar Analyst Report for Exelixis Inc

      Stock Reports

      Fri, 1 Aug 2014

      While Exelixis boasts a vast clinical lineup, only one of its drugs has ..... Cometriq, thus raising questions about the full potential of Exelixis ' key oncology program.Although Exelixis ' diverse clinical lineup helps distinguish it from its

    5. Exelixis' ( EXEL ) CEO Michael Morrissey On Q2 2014 Results - Earnings Call Transcript

      Headlines

      Thu, 31 Jul 2014

      Exelixis , Inc. (NASDAQ: EXEL ) Q2 2014 Earnings Conference Call July 31, 2014 05:00 PM ET ..... Presentation Operator Good day ladies and gentlemen and welcome to the Exelixis ’ Second Quarter 2014 Financial Results Conference Call. My name

    6. More on Exelixis Q2 results

      Headlines

      Thu, 31 Jul 2014

      Exelixis ( EXEL -5.6% ) Q2 results : Total Revenues: $6.6M (-44.7%); Operating Expenses: $68.3M (+8.1%); Operating Loss

    7. Exelixis' Rumored Acquisition And Large Pipeline Offer Short-Term Gains, Long-Term Sustainability

      Headlines

      Mon, 28 Jul 2014

      point for investors in Exelixis , Inc. (NASDAQ: EXEL ). Since the company ..... treatment to market now. Exelixis has two primary cancer ..... cobimetinib ((Cobi)). Exelixis has a partnership with ..... of the agreement, ( EXEL ) receives 50% of the

    8. New Morningstar Analyst Report for Biogen Idec Inc

      Stock Reports

      Wed, 23 Jul 2014

      as CEO of development-stage biotech Exelixis for 14 years. While we see this as an ..... operations, we think his performance at Exelixis demonstrates a strong understanding of ..... by Stelios Papadopoulos (chairman at Exelixis and Regulus) at Biogen's annual meeting

    9. Traders pile into Exelixis

      Headlines

      Mon, 14 Jul 2014

      Shares of Exelixis ( EXEL +21.8% ) romp on massive turnover of over 33M shares in response to this morning's report of positive results in a Phase

    10. Midday Gainers / Losers

      Headlines

      Mon, 14 Jul 2014

      Top 10 Gainers: GRH +22% . SCOK +20% . KNDI +17% . ULTR +16% . PHX +15% . RADA +13% . EXEL +13% . URS +12% . CBAK +12% . CREG +13% . Top 10 Losers: VISN -14% . FHCO -13% . HLIT -11% . INVT -9% . GIGA -9

    « Prev12345Next »
    Content Partners